A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 8, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

DRUG

EU103

EU103 will be administered via intravenous infusion.

Trial Locations (3)

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Samsung Seoul Hospital, Seoul

RECRUITING

Seoul National University Hospital, Seoul